cancer immunotherapy

Pharma By Adam Feuerstein

Is ‘STING’ a new and promising cancer target? Don’t look at Merck’s study results for a definitive answer

Adam's Take By Adam Feuerstein

The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize

Pharma By Adam Feuerstein

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

Health By Associated Press

Some immune-boosting cancer drugs may pose rare heart risks

Biotech By Arlene Weintraub

A biotech firm, on the brink of ruin, resurrects itself via man — and microbe